Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials
ABSTRACT Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
bioRxiv.org - (2021) vom: 25. Juni Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Talasaz, Azita H. [VerfasserIn] |
|---|
| Links: |
|---|
| doi: |
10.1101/2021.01.04.21249227 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019698046 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019698046 | ||
| 003 | DE-627 | ||
| 005 | 20230429094702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210108s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.01.04.21249227 |2 doi | |
| 035 | |a (DE-627)XBI019698046 | ||
| 035 | |a (biorXiv)10.1101/2021.01.04.21249227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Talasaz, Azita H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Endothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs. | ||
| 700 | 1 | |a Sadeghipour, Parham |e verfasserin |4 aut | |
| 700 | 1 | |a Kakavand, Hessam |e verfasserin |4 aut | |
| 700 | 1 | |a Aghakouchakzadeh, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Kordzadeh-Kermani, Elaheh |e verfasserin |4 aut | |
| 700 | 1 | |a Van Tassell, Benjamin W. |e verfasserin |4 aut | |
| 700 | 1 | |a Gheymati, Azin |e verfasserin |4 aut | |
| 700 | 1 | |a Ariannejad, Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Hosseini, Seyed Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Jamalkhani, Sepehr |e verfasserin |4 aut | |
| 700 | 1 | |a Sholzberg, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Monreal, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, David |e verfasserin |4 aut | |
| 700 | 1 | |a Piazza, Gregory |e verfasserin |4 aut | |
| 700 | 1 | |a Parikh, Sahil A. |e verfasserin |4 aut | |
| 700 | 1 | |a Kirtane, Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Eikelboom, John W. |e verfasserin |4 aut | |
| 700 | 1 | |a Connors, Jean M. |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Beverley J. |e verfasserin |4 aut | |
| 700 | 1 | |a Konstantinides, Stavros V. |e verfasserin |4 aut | |
| 700 | 1 | |a Cushman, Mary |e verfasserin |4 aut | |
| 700 | 1 | |a Weitz, Jeffrey I. |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, Gregg W. |e verfasserin |4 aut | |
| 700 | 1 | |a Krumholz, Harlan M. |e verfasserin |4 aut | |
| 700 | 1 | |a Lip, Gregory Y.H. |e verfasserin |4 aut | |
| 700 | 1 | |a Goldhaber, Samuel Z. |e verfasserin |4 aut | |
| 700 | 1 | |a Bikdeli, Behnood |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2021) vom: 25. Juni |
| 773 | 1 | 8 | |g year:2021 |g day:25 |g month:06 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jacc.2021.02.035 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.01.04.21249227 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 25 |c 06 | ||
| 953 | |2 045F |a 570 | ||